Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission (NCT06824168)

🧪 Interventions in This Study

• Quizartinib High Dose (DRUG)
• Quizartinib Low Dose (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (58 Sites)

Showing the first 25 of 58 sites.

• John Hopkins School of Medicine — Baltimore, Maryland
• Umass Memorial Health Care Systems — Worcester, Massachusetts
• Roswell Park Cancer Institute — Buffalo, New York
• Weill Cornell — New York, New York
• Westchester Medical College — Valhalla, New York
• Clinical Research Allicance — Westbury, New York
• Spoknwrd Clinical Trials Inc. — Easton, Pennsylvania
• The Methodist Hospital Research Institute — Houston, Texas
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• Royal Adelaide Hospital — Adelaide,
• Austin Health — Australia,
• St. Vincent's Hospital Melbourne — Darlinghurst,
• The Alfred Hospital — Melbourne,
• Royal Perth Hospital — Perth,
• Gold Coast University Hospital — Southport,
• Westmead Hospital — Sydney,
• Hospital Erasto Gaertner - Liga Paranaense de Combate ao Cancer — Curitiba,
• Cetus Hospital Dia Oncologia — Minas Gerai,
• Hospital de Clínicas de Porto Alegre — Porto Alegre,
• Irmandade da Santa Casa de Misericórdia de Porto Alegre Centro Multidisciplinar de Pesquisa — Porto Alegre,
• INCA - Instituto Nacional de Câncer — Rio de Janeiro,
• "Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto CIP - Centro Integrado de Pesquisa" — San Jose Rio Preto,
• Hospital Santa Marcelina — São Paulo,
• ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira — São Paulo,
• Peking Union Medical College Hospital — Beijing,

📞 Contact the Study Coordinator

Phone: (908) 992-6400

Email: CTRinfo_us@daiichisankyo.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia

• PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
• Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
• A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
• A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California

Explore by condition: All Acute Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.